Literature DB >> 12649173

Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines.

Cinzia Sevignani1, George A Calin, Rossano Cesari, Manuela Sarti, Hideshi Ishii, Sai Yendamuri, Andrea Vecchione, Francesco Trapasso, Carlo M Croce.   

Abstract

The fragile histidine triad (FHIT) gene at chromosome 3p14.2 is a tumor suppressor gene that is altered mainly by deletion in a large fraction of human tumors, including breast cancers. To evaluate the potential of FHIT gene therapy in this type of cancer, we have studied the biological effects of adenoviral FHIT transduction (Ad-FHIT) in breast cancer cell lines. The results showed that, after FHIT restoration in BT-549, MDA-MB-436, and HCC1806 cells, they underwent apoptosis by activation of the intrinsic pathway. In all three cell lines infected with Ad-FHIT, we have found activation of caspase-2, which is required for permeabilization of mitochondria, release of cytochrome c, and apoptosis. Furthermore, Fhit overexpression produces alteration in cell cycling properties, as well as reduction of the tumorigenic potential in nude mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649173

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  FHIT promoter DNA methylation and expression analysis in childhood acute lymphoblastic leukemia.

Authors:  Gholamreza Bahari; Mohammad Hashemi; Majid Naderi; Simin Sadeghi-Bojd; Mohsen Taheri
Journal:  Oncol Lett       Date:  2017-08-23       Impact factor: 2.967

2.  High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis.

Authors:  Roberto Jose Diaz; Mustafa Guduk; Rocco Romagnuolo; Christian A Smith; Paul Northcott; David Shih; Fitim Berisha; Adrienne Flanagan; David G Munoz; Michael D Cusimano; M Necmettin Pamir; James T Rutka
Journal:  Neoplasia       Date:  2012-09       Impact factor: 5.715

3.  Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular carcinoma.

Authors:  Juliette Martin; Fabrice Magnino; Karin Schmidt; Anne-Christine Piguet; Ju-Seog Lee; David Semela; Marie V St-Pierre; Andrew Ziemiecki; Doris Cassio; Charles Brenner; Snorri S Thorgeirsson; Jean-François Dufour
Journal:  Gastroenterology       Date:  2006-06       Impact factor: 22.682

4.  A knockdown with smoke model reveals FHIT as a repressor of Heme oxygenase 1.

Authors:  Jennifer A Boylston; Charles Brenner
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

5.  Frequent epigenetic silencing of the FHIT gene in penile squamous cell carcinomas.

Authors:  Naoki Yanagawa; Mitsumasa Osakabe; Masahiro Hayashi; Gen Tamura; Teiichi Motoyama
Journal:  Virchows Arch       Date:  2008-02-26       Impact factor: 4.064

6.  Mammalian nitrilase 1 homologue Nit1 is a negative regulator in T cells.

Authors:  Haibing Zhang; Ying-Ju Hou; Shuang-Yin Han; Eric C Zhang; Kay Huebner; Jianke Zhang
Journal:  Int Immunol       Date:  2009-04-24       Impact factor: 4.823

7.  Characterization of the role of Fhit in suppression of DNA damage.

Authors:  Joshua C Saldivar; Jessica Bene; Seyed Ali Hosseini; Satoshi Miuma; Susan Horton; Nyla A Heerema; Kay Huebner
Journal:  Adv Biol Regul       Date:  2012-10-11

8.  Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential.

Authors:  S Semba; F Trapasso; M Fabbri; K A McCorkell; S Volinia; T Druck; D Iliopoulos; Y Pekarsky; H Ishii; P N Garrison; L D Barnes; C M Croce; K Huebner
Journal:  Oncogene       Date:  2006-05-11       Impact factor: 8.756

9.  Recombinant AAV-mediated HSVtk gene transfer with direct intratumoral injections and Tet-On regulation for implanted human breast cancer.

Authors:  Zi-Bo Li; Zhao-Jun Zeng; Qian Chen; Sai-Qun Luo; Wei-Xin Hu
Journal:  BMC Cancer       Date:  2006-03-16       Impact factor: 4.430

10.  Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant.

Authors:  M Ottey; S-Y Han; T Druck; B L Barnoski; K A McCorkell; C M Croce; C Raventos-Suarez; C R Fairchild; Y Wang; K Huebner
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.